Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Revenue (2016 - 2025)

Historic Revenue for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $36.4 million.

  • Lifecore Biomedical, Inc. \De\'s Revenue fell 380.62% to $36.4 million in Q2 2025 from the same period last year, while for May 2025 it was $128.9 million, marking a year-over-year increase of 47.17%. This contributed to the annual value of $128.9 million for FY2025, which is 47.25% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Revenue amounted to $36.4 million in Q2 2025, which was down 380.62% from $35.2 million recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Revenue high stood at $44.9 million for Q2 2021, and its period low was $21.9 million during Q4 2022.
  • For the 5-year period, Lifecore Biomedical, Inc. \De\'s Revenue averaged around $30.2 million, with its median value being $29.1 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 8181.69% in 2021, then skyrocketed by 3789.79% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Revenue (Quarter) stood at $25.6 million in 2021, then fell by 14.6% to $21.9 million in 2022, then soared by 37.9% to $30.2 million in 2023, then rose by 8.01% to $32.6 million in 2024, then increased by 11.91% to $36.4 million in 2025.
  • Its Revenue stands at $36.4 million for Q2 2025, versus $35.2 million for Q1 2025 and $32.6 million for Q4 2024.